Biomarkers in Parkinsonian Syndromes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-23

Study Completion Date

2030-03-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective observational study to identify biomarkers in parkinson syndromes. Patients with parkinsonian syndromes at the early stages of disease will be recruited and will be followed up until their established clinical diagnosis or for at least 5 years. In this population, imaging and wet biomarkers as well as clinical data will b systematically collected.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Serum Biomarkers in Parkinson's Disease at Different Stages

NCT05769699

Parkinson Disease

RECRUITING NA

NMR Based Metabolomic Study of Serum Biomarkers in Patients With Parkinson's Disease and Atypical Parkinsonian Syndrome

NCT06490926

Progressive Supranuclear Palsy Multiple System Atrophy Parkinson's Disease

RECRUITING

Research of Biomarkers in Parkinson Disease

NCT00465790

Parkinson Disease Multiple System Atrophy Progressive Supranuclear Palsy +3 more

COMPLETED

Parkinson's Repository of Biosamples and Network Datasets (Tracking Parkinson's)

NCT02881099

Parkinson's Disease

COMPLETED

Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression

NCT01141023

Parkinson Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease Progressive Supranuclear Palsy Multiple System Atrophy Atypical Parkinsonism Parkinsonism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Drug-induced parkinsonism (eg, neuroleptics, lithium, valproic acid, metoclopramide).
* Metabolic conditions related parkinsonism (eg, Wilson's disease, hypoparathyroidism).
* Structural lesions on brain magnetic resonance imaging (MRI) that explain the symptoms, such as normal pressure hydrocephalus, moderate to severe chronic vascular encephalopathy, cerebral infarction, neoplasm
* Other serious diseases that indicate a life expectancy of \<5 years.
* Active participation in other interventional clinical studies

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes